Drug profile · INN
levalbuterol tartrate
XOPENEX HFA
levalbuterol tartrate (XOPENEX HFA) is a beta-2 adrenergic receptor agonist. Route of administration: inhalation. Current US regulatory status: approved.
Drug details — levalbuterol tartrate
- US status
- approved
- Class
- —
- Route
- INHALATION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
levalbuterol tartrate (XOPENEX HFA) is a beta-2 adrenergic receptor agonist. Route of administration: inhalation. Current US regulatory status: approved.
Key facts
Mechanism of action
Beta-2 adrenergic receptor agonist
Primary target: Beta-2 adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is levalbuterol tartrate?
levalbuterol tartrate (XOPENEX HFA) is a beta-2 adrenergic receptor agonist. Route of administration: inhalation. Current US regulatory status: approved.
What is the brand name for levalbuterol tartrate?
XOPENEX HFA is a marketed brand name for levalbuterol tartrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of levalbuterol tartrate?
levalbuterol tartrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.